Search Result "P50 auditory evoked potential suppression"
Filtering Disturbances in Schizophrenic Patients. Gating of Auditory Evoked Potentials and Prepulse Inhibition of the Acoustic Startle Response Compared. Emphasis on the Role of Dopamine
Journal: Current Neuropharmacology
Volume: 1 Issue: 1 Year: 2003 Page: 47-87
Author(s): N. M.W.J. de Bruin, E. L.J.M. van Luijtelaar, A. R. Cools, B. A. Ellenbroek
α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia
Journal: Current Pharmaceutical Design
Volume: 17 Issue: 2 Year: 2011 Page: 121-129
Author(s): Masatomo Ishikawa, Kenji Hashimoto
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Journal: Current Pharmaceutical Design
Volume: 21 Issue: 26 Year: 2015 Page: 3797-3806
Author(s): Kenji Hashimoto
α7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia
Journal: Current Medicinal Chemistry - Central Nervous System Agents
Volume: 5 Issue: 3 Year: 2005 Page: 171-184
Author(s): Kenji Hashimoto, Kaori Koike, Eiji Shimizu, Masaomi Iyo
Neurophysiological Effects of Cannabinoids: Implications for Psychosis Research
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 32 Year: 2012 Page: 4938-4949
Author(s): Jurgen Gallinat,Johannes Rentzsch,Patrik Roser
Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Journal: Current Pharmaceutical Design
Volume: 16 Issue: 5 Year: 2010 Page: 538-554
Author(s): Mihaly Hajos, Bruce N. Rogers
Sensory Perception Abnormalities in People at Clinical High-Risk for Psychosis and Those with First-Episode Psychosis
Journal: Current Psychiatry Reviews
Volume: 12 Issue: 4 Year: 2016 Page: 335-342
Author(s): Emily K. Bell
Neurophysiological Alterations in the Prepsychotic Phases
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 4 Year: 2012 Page: 479-485
Author(s): Nicolas A. Crossley, Miguel Constante, Paolo Fusar-Poli, Elvira Bramon
Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Journal: Current Pharmaceutical Design
Volume: 22 Issue: 14 Year: 2016 Page: 2093-2116
Author(s): Agnieszka Nikiforuk
Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Journal: Current Pharmaceutical Design
Volume: 16 Issue: 3 Year: 2010 Page: 309-322
Author(s): Richard J. Radek, Kathy L. Kohlhaas, Lynne E. Rueter, Eric G. Mohler